Total raised: $93.5M
Funding Rounds 1
| Date | Series | Amount | Investors |
| 14.02.2025 | Series A | $93.5M | - |
Mentions in press and media 4
| Date | Title | Description |
| 15.02.2025 | Newleos Therapeutics: A New Dawn in Neuropsychiatric Treatment | In the world of mental health, the need for innovation is as urgent as a fire alarm. Newleos Therapeutics has stepped into this arena with a bold vision and a hefty $93.5 million in Series A funding. This clinical-stage neuroscience company... |
| 14.02.2025 | Newleos Therapeutics: $93.5 Million (Series A) Raised For Transforming Treatment Of Neuropsychiatric Disorders | Newleos Therapeutics—a clinical-stage neuroscience company co-founded by Longwood Fund and seasoned leaders in CNS drug development—announced the closing of an oversubscribed $93.5 million Series A financing. Goldman Sachs Alternatives led ... |
| 13.02.2025 | Newleos Therapeutics Debuts with $93.5 Million Oversubscribed Series A Financing to Transform the Treatment of Neuropsychiatric Disorders through the Advancement of Novel Medicines | -Newleos aims to develop first-in-class and best-in-class therapies to address the need for safer and more efficacious treatment options for major mental health conditions- -Multiple clinical-stage programs licensed from Roche, ready for pr... |
| - | Newleos Therapeutics | “Newleos – A new dawn for treatment of mental health conditions” |